The Data Safety Monitoring Board for two clinical trials of Galena Biopharma Inc.'s (Nasdaq: GALE) breast cancer treatment NeuVax found no safety concerns with either trial. The stock price rose 21 cents to close at $1.41.
No safety concerns with Galena Biopharma's NeuVax
February 06, 2017 at 17:46 PM EST
